Histological and molecular characterization of TFEB-rearranged renal cell carcinomas

  • Nicolas Wyvekens
  • Markus Rechsteiner
  • Christine Fritz
  • Ulrich Wagner
  • Joëlle Tchinda
  • Carina Wenzel
  • Friederike Kuithan
  • Lars-Christian Horn
  • Holger MochEmail author
Brief Report


The 2016 WHO Classification of Tumors of the Urinary System recognizes microphthalmia transcription factor (MiT) family translocation carcinomas as a separate entity among renal cell carcinomas. TFE3 and transcription factor EB (TFEB) are members of the MiT family for which chromosomal rearrangements have been associated with renal cell carcinoma formation. TFEB translocation renal cell carcinoma is a rare tumor harboring a t(6;11)(p21;q12) translocation. Recently, renal cell carcinomas with TFEB amplification have been identified. TFEB amplified renal cell carcinomas have to be distinguished from TFEB-translocated renal cancer, because they may demonstrate a more aggressive behavior. Herein, we present a TFEB-translocated and a TFEB-amplified carcinoma cases and describe their distinct histological, immunohistochemical, and molecular characteristics. In addition, we review conventional morphology, immunophenotype, genetic background, and clinical outcome of TFEB-rearranged RCCs in the literature, with a special emphasis on important differential diagnoses and the diagnostic approach.


MITF TFEB Translocation Amplification Renal cell carcinoma RCC 


Authors’ contributions

N. W. and H. M. conceived and designed the study; provided histological descriptions of tumors; reviewed the literature; and wrote, edited, and reviewed the manuscript. C. W., F. K., and L.-C. H. provided FFPE tumor samples, clinical information, and macroscopic descriptions of tumors. M. R. and C. F. performed RNA sequencing. U. W. analyzed RNA sequencing data. J. T. performed the aCGH experiment and analyzed aCGH data. All authors critically read the manuscript, gave final approval for publication, and took full responsibility for the work as a whole.


This study was supported by the Swiss National Science Foundation (SNSF grant number S-87701-03-01).

Compliance with ethical standards

This study was approved by the ethics commission of the Canton Zurich. Formalin-fixed paraffin-embedded (FFPE) samples of both tumors were sent to the University Hospital Zurich as consult cases.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

428_2019_2526_MOESM1_ESM.xlsx (18 kb)
Supplementary Table 1 Clinicopathological characteristics of t(6;11) renal cell carcinomas in the literature [4, 8, 9, 10, 11, 12, 15, 16, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45]. F female; M male; NA not available; NED no evidence of disease; + diffuse or focal staining; − no staining; * one of these three cases positive for HMB45; ** five of the six cases positive for HMB45 or MelanA. (XLSX 17 kb)
428_2019_2526_MOESM2_ESM.xlsx (15 kb)
Supplementary Table 2 Clinicopathological characteristics of TFEB amplified renal cell carcinomas in the literature [15, 16, 17, 19, 20, 21, 44, 46]. F female; M male; NA not available; NED no evidence of disease; + diffuse or focal staining; − no staining. (XLSX 15 kb)


  1. 1.
    Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs—part a: renal, penile, and testicular tumours. Eur Urol 70:93–105. CrossRefGoogle Scholar
  2. 2.
    Inamura K (2017) Translocation renal cell carcinoma: an update on clinicopathological and molecular features. Cancers 9:111. CrossRefGoogle Scholar
  3. 3.
    Zhan H-Q, Li S-T, Shu Y, Liu MM, Qin R, Li YL, Gan L (2018) Alpha gene upregulates TFEB expression in renal cell carcinoma with t(6;11) translocation, which promotes cell canceration. Int J Oncol 52:933–944. Google Scholar
  4. 4.
    Davis IJ, Hsi B-L, Arroyo JD, Vargas SO, Yeh YA, Motyckova G, Valencia P, Perez-Atayde AR, Argani P, Ladanyi M, Fletcher JA, Fisher DE (2003) Cloning of an alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci 100:6051–6056. CrossRefGoogle Scholar
  5. 5.
    Ge H, Liu K, Juan T, Fang F, Newman M, Hoeck W (2011) FusionMap: detecting fusion genes from next-generation sequencing data at base-pair resolution. Bioinformatics 27:1922–1928. CrossRefGoogle Scholar
  6. 6.
    Panagopoulos I, Gorunova L, Bjerkehagen B, Heim S (2014) The “grep” command but not FusionMap, FusionFinder or ChimeraScan captures the CIC-DUX4 fusion gene from whole transcriptome sequencing data on a small round cell tumor with t(4;19)(q35;q13). PLoS One 9:e99439. CrossRefGoogle Scholar
  7. 7.
    Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, Srinivasan R, Linehan WM (2014) Molecular genetics and cellular characteristics of TFE3 and TFEB translocation renal cell carcinomas. Nat Rev Urol 11:465–475. CrossRefGoogle Scholar
  8. 8.
    Inamura K, Fujiwara M, Togashi Y, Nomura K, Mukai H, Fujii Y, Yamamoto S, Yonese J, Fukui I, Ishikawa Y (2012) Diverse fusion patterns and heterogeneous Clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol 36:35–42. CrossRefGoogle Scholar
  9. 9.
    Dijkhuizen T, van den Berg E, Störkel S et al (1996) In abstract form. two cases of renal cell carcinoma, clear cell type, revealing a t(6;11)(p21;q13). Cancer Genet Cytogenet 91:141. CrossRefGoogle Scholar
  10. 10.
    Argani P, Hawkins A, Griffin CA, Goldstein JD, Haas M, Beckwith JB, Mankinen CB, Perlman EJ (2001) A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol 158:2089–2096CrossRefGoogle Scholar
  11. 11.
    Caliò A, Brunelli M, Segala D, Pedron S, Tardanico R, Remo A, Gobbo S, Meneghelli E, Doglioni C, Hes O, Zampini C, Argani P, Martignoni G (2018) t(6;11) renal cell carcinoma: a study of seven cases including two with aggressive behavior, and utility of CD68 (PG-M1) in the differential diagnosis with pure epithelioid PEComa/epithelioid angiomyolipoma. Mod Pathol 31:474–487. CrossRefGoogle Scholar
  12. 12.
    Argani P, Yonescu R, Morsberger L, Morris K, Netto GJ, Smith N, Gonzalez N, Illei PB, Ladanyi M, Griffin CA (2012) Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol 36:1516–1526. CrossRefGoogle Scholar
  13. 13.
    Williamson SR, Eble JN, Palanisamy N (2017) Sclerosing TFEB-rearrangement renal cell carcinoma: a recurring histologic pattern. Hum Pathol 62:175–179. CrossRefGoogle Scholar
  14. 14.
    Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D, Pan CC, Netto G, Doglioni C, Hes O, Argani P, Chilosi M (2009) Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol 22:1016–1022. CrossRefGoogle Scholar
  15. 15.
    Peckova K, Vanecek T, Martinek P, Spagnolo D, Kuroda N, Brunelli M, Vranic S, Djuricic S, Rotterova P, Daum O, Kokoskova B, Vesela P, Pivovarcikova K, Bauleth K, Dubova M, Kalusova K, Hora M, Michal M, Hes O (2014) Aggressive and nonaggressive translocation t(6;11) renal cell carcinoma: comparative study of 6 cases and review of the literature. Ann Diagn Pathol 18:351–357. CrossRefGoogle Scholar
  16. 16.
    Argani P, Reuter VE, Zhang L, Sung YS, Ning Y, Epstein JI, Netto GJ, Antonescu CR (2016) TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic heterogeneity. Am J Surg Pathol 40:1484–1495. CrossRefGoogle Scholar
  17. 17.
    Gupta S, Johnson SH, Vasmatzis G, Porath B, Rustin JG, Rao P, Costello BA, Leibovich BC, Thompson RH, Cheville JC, Sukov WR (2017) TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management. Mod Pathol 30:998–1012. CrossRefGoogle Scholar
  18. 18.
    Delahunt B, Cheville JC, Martignoni G, Humphrey PA, Magi-Galluzzi C, McKenney J, Egevad L, Algaba F, Moch H, Grignon DJ, Montironi R, Srigley JR, Members of the ISUP Renal Tumor Panel (2013) The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 37:1490–1504. CrossRefGoogle Scholar
  19. 19.
    Mendel L, Ambrosetti D, Bodokh Y et al (2018) Comprehensive study of three novel cases of TFEB-amplified renal cell carcinoma and review of the literature: Evidence for a specific entity with poor outcome. Genes Chromosomes Cancer 57:99–113. CrossRefGoogle Scholar
  20. 20.
    Williamson SR, Grignon DJ, Cheng L, Favazza L, Gondim DD, Carskadon S, Gupta NS, Chitale DA, Kalyana-Sundaram S, Palanisamy N (2017) Renal cell carcinoma with chromosome 6p amplification including the TFEB gene: a novel mechanism of tumor pathogenesis? Am J Surg Pathol 41:287–298. CrossRefGoogle Scholar
  21. 21.
    Skala SL, Xiao H, Udager AM, Dhanasekaran SM, Shukla S, Zhang Y, Landau C, Shao L, Roulston D, Wang L, Siddiqui J, Cao X, Magi-Galluzzi C, Zhang M, Osunkoya AO, Smith SC, McKenney JK, Betz BL, Myers JL, Chinnaiyan AM, Tomlins SA, Mehra R (2018) Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays. Mod Pathol 31:179–197. CrossRefGoogle Scholar
  22. 22.
    Sukov WR, Hodge JC, Lohse CM, Leibovich BC, Thompson RH, Pearce KE, Wiktor AE, Cheville JC (2012) TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients. Am J Surg Pathol 36:663–670. Google Scholar
  23. 23.
    Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P, ISUP Renal Tumor Panel (2013) The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol 37:1469–1489. CrossRefGoogle Scholar
  24. 24.
    Kuiper RP, Schepens M, Thijssen J, van Asseldonk M, van den Berg E, Bridge J, Schuuring E, Schoenmakers EF, van Kessel A (2003) Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Hum Mol Genet 12:1661–1669. CrossRefGoogle Scholar
  25. 25.
    Argani P, Laé M, Hutchinson B et al (2005) Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol 29:230–240CrossRefGoogle Scholar
  26. 26.
    Argani P, Ladanyi M (2005) Translocation carcinomas of the kidney. Clin Lab Med 25:363–378. CrossRefGoogle Scholar
  27. 27.
    Argani P, Laé M, Ballard ET, Amin M, Manivel C, Hutchinson B, Reuter VE, Ladanyi M (2006) Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol 24:1529–1534. CrossRefGoogle Scholar
  28. 28.
    Pecciarini L, Cangi MG, Cunsolo CL et al (2007) Characterization of t(6;11)(p21;q12) in a renal-cell carcinoma of an adult patient. Genes Chromosomes Cancer 46:419–426. CrossRefGoogle Scholar
  29. 29.
    Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, Furge KA, Comperat EM, Lae M, Bouvier R, Boccon-Gibod L, Denoux Y, Ferlicot S, Forest E, Fromont G, Hintzy MC, Laghouati M, Sibony M, Tucker ML, Weber N, Teh BT, Vieillefond A (2008) Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol 32:656–670. CrossRefGoogle Scholar
  30. 30.
    Hora M, Hes O, Urge T et al (2009) A distinctive translocation carcinoma of the kidney [“rosette-like forming,” t(6;11), HMB45-positive renal tumor]. Int Urol Nephrol 41:553–557. CrossRefGoogle Scholar
  31. 31.
    Zhan H-Q, Wang C-F, Zhu X-Z, Xu X-L (2010) Renal cell carcinoma with t(6;11) translocation: a patient case with a novel alpha-TFEB fusion point. J Clin Oncol 28:e709–e713. CrossRefGoogle Scholar
  32. 32.
    Malouf GG, Camparo P, Molinié V, Dedet G, Oudard S, Schleiermacher G, Theodore C, Dutcher J, Billemont B, Bompas E, Guillot A, Boccon-Gibod L, Couturier J, Escudier B (2011) Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. J Urol 185:24–29. CrossRefGoogle Scholar
  33. 33.
    Suárez-Vilela D, Izquierdo-García F, Méndez-Álvarez JR, Miguélez-García E, Domínguez-Iglesias F (2011) Renal translocation carcinoma with expression of TFEB: presentation of a case with distinctive histological and immunohistochemical features. Int J Surg Pathol 19:506–509. CrossRefGoogle Scholar
  34. 34.
    Ishihara A, Yamashita Y, Takamori H, Kuroda N (2011) Renal carcinoma with (6;11)(p21;q12) translocation: Report of an adult case. Pathol Int 61:539–545. CrossRefGoogle Scholar
  35. 35.
    Petersson F, Vaněček T, Michal M, Martignoni G, Brunelli M, Halbhuber Z, Spagnolo D, Kuroda N, Yang X, Cabrero IA, Hora M, Branžovský J, Trivunic S, Kacerovská D, Steiner P, Hes O (2012) A distinctive translocation carcinoma of the kidney; “rosette forming,” t(6;11), HMB45-positive renal tumor: a histomorphologic, immunohistochemical, ultrastructural, and molecular genetic study of 4 cases. Hum Pathol 43:726–736. CrossRefGoogle Scholar
  36. 36.
    Rao Q, Liu B, Cheng L et al (2012) Renal cell carcinomas with t(6;11)(p21;q12): a clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol 36:1327. CrossRefGoogle Scholar
  37. 37.
    Zhong M, De Angelo P, Osborne L et al (2012) Translocation renal cell carcinomas in adults: a single institution experience. Am J Surg Pathol 36:654–662. CrossRefGoogle Scholar
  38. 38.
    Rao Q, Zhang X-M, Tu P, Xia QY, Shen Q, Zhou XJ, Shi QL (2013) Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features. Int J Clin Exp Pathol 6:1452–1457Google Scholar
  39. 39.
    Matsuura K, Inoue T, Kai T, Yano S, Kashima K, Yokoyama S, Sato F, Nomura T, Mimata H, Moriyama M, Kuroda N, Nagashima Y (2014) Molecular analysis of a case of renal cell carcinoma with t(6;11)(p21;q12) reveals a link to a lysosome-like structure. Histopathology 64:306–309. CrossRefGoogle Scholar
  40. 40.
    Smith NE, Illei PB, Allaf M, Gonzalez N, Morris K, Hicks J, DeMarzo A, Reuter VE, Amin MB, Epstein JI, Netto GJ, Argani P (2014) T(6;11) renal cell carcinoma (RCC) expanded Immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol 38:604–614. CrossRefGoogle Scholar
  41. 41.
    Arneja SK, Gujar N (2015) Renal cell carcinoma with t(6:11) (p21;q12). A case report highlighting distinctive immunohistologic features of this rare tumor. Int J Surg Case Rep 7:16–19. CrossRefGoogle Scholar
  42. 42.
    Lilleby W, Vlatkovic L, Meza-Zepeda LA et al (2015) Translocational renal cell carcinoma (t(6;11)(p21;q12)) with transcription factor EB (TFEB) amplification and an integrated precision approach: a case report. J Med Case Rep 9:281. CrossRefGoogle Scholar
  43. 43.
    Kuroda N, Yorita K, Sasaki N, Ishihara A, Matsuura K, Daa T, Mori S, Sasaki A, Mikami S, Shigematsu K, Nagashima Y (2017) Clinicopathological study of 5 cases of renal cell carcinoma with t(6;11)(p21;q12). Pol J Pathol 68:66–72. CrossRefGoogle Scholar
  44. 44.
    Martin EE, Mehra R, Jackson-Cook C, Smith SC (2017) Renal cell carcinoma with TFEB translocation versus unclassified renal cell carcinoma with TFEB amplification. AJSP Rev Rep 22:305. Google Scholar
  45. 45.
    Cajaiba MM, Dyer LM, Geller JI, Jennings LJ, George D, Kirschmann D, Rohan SM, Cost NG, Khanna G, Mullen EA, Dome JS, Fernandez CV, Perlman EJ (2018) The classification of pediatric and young adult renal cell carcinomas registered on the Children’s Oncology Group (COG) protocol AREN03B2 after focused genetic testing. Cancer 124:3381–3389. CrossRefGoogle Scholar
  46. 46.
    Durinck S, Stawiski EW, Pavía-Jiménez A, Modrusan Z, Kapur P, Jaiswal BS, Zhang N, Toffessi-Tcheuyap V, Nguyen TT, Pahuja KB, Chen YJ, Saleem S, Chaudhuri S, Heldens S, Jackson M, Peña-Llopis S, Guillory J, Toy K, Ha C, Harris CJ, Holloman E, Hill HM, Stinson J, Rivers CS, Janakiraman V, Wang W, Kinch LN, Grishin NV, Haverty PM, Chow B, Gehring JS, Reeder J, Pau G, Wu TD, Margulis V, Lotan Y, Sagalowsky A, Pedrosa I, de Sauvage FJ, Brugarolas J, Seshagiri S (2015) Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes. Nat Genet 47:13–21. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Nicolas Wyvekens
    • 1
  • Markus Rechsteiner
    • 1
  • Christine Fritz
    • 1
  • Ulrich Wagner
    • 1
  • Joëlle Tchinda
    • 2
  • Carina Wenzel
    • 3
  • Friederike Kuithan
    • 3
  • Lars-Christian Horn
    • 4
  • Holger Moch
    • 1
    Email author
  1. 1.Department of Pathology and Molecular PathologyUniversity Hospital and University ZurichZurichSwitzerland
  2. 2.Department of OncologyUniversity Children’s Hospital ZurichZurichSwitzerland
  3. 3.Department of Pathology, University Hospital Carl Gustav CarusTechnische Universität DresdenDresdenGermany
  4. 4.Institute of PathologyUniversity Hospital LeipzigLeipzigGermany

Personalised recommendations